Real-World Clinical Experience With Monthly Faricimab for Treatment-Naïve Diabetic Macular Edema: A Case Series From an Indian Tertiary Care Center.

This case series explores the efficacy and safety of a monthly loading dose regimen of intravitreal faricimab in treatment-naïve patients with diabetic macular edema (DME) in an Indian clinical setting. In this retrospective analysis, five adult patients with treatment-naïve DME received faricimab (four intravitreal injections of 6 mg) on Day 0, Day 30, Day 60, and Day 90. Their best-corrected visual acuity (BCVA) and central macular thickness (CMT) were evaluated throughout the study. Additional outcome measures included adverse events and patient-reported treatment satisfaction, graded from "very satisfied" to "not satisfied." All patients exhibited notable improvements in BCVA alongside significant reductions in CMT over the three-month follow-up period, achieving marked anatomical recovery. Visual gains were notably greater in patients with a shorter duration of diabetes and better baseline vision. No ocular adverse events were observed during the study. Overall, patient satisfaction scores improved from "moderate" at baseline to "very satisfied" by the end of follow-up. These findings suggest that monthly loading doses of intravitreal faricimab are favorable for treating treatment-naïve DME patients. The results reinforce faricimab's potential to improve disease management, offering both safety and efficacy in real-world clinical settings.